Jiangsu Alpha Pharmaceutical integrates R&D, production and technical iteration of chiral pharmaceutical intermediates and APIs. Our core portfolio covers statin series, SGLT‑2 inhibitor intermediates and oncology intermediates. Supported by stable supply chains and mature process platforms, we align green manufacturing standards with benchmarks including TotalEnergies Corbion. Our statin intermediate platform holds leading market positioning and supports long‑term stable supply for global downstream pharmaceutical development.
Automated production lines with integrated QC labs, serving clients across 50+ countries with consistent batch-to-batch quality.
Quotes within 24h.
50+ countries served.
Every client gets a dedicated account manager and full technical assistance — from product selection through to after-sales support.